Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study

Welte, 2012, Clinical and economic burden of community-acquired pneumonia among adults in Europe, Thorax, 67, 71, 10.1136/thx.2009.129502 Peto, 2014, The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review, Trans R Soc Trop Med Hyg, 108, 326, 10.1093/trstmh/tru058 Jain, 2015, Community-acquired pneumonia requiring hospitalization among U.S. adults, N Engl J Med, 373, 415, 10.1056/NEJMoa1500245 Said, 2013, Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques, PLoS One, 8, e60273, 10.1371/journal.pone.0060273 Morimoto, 2015, The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study, PLoS One, 10, e0122247, 10.1371/journal.pone.0122247 Tomczyk, 2014, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 63, 822 Huss, 2009, Efficacy of pneumococcal vaccination in adults: a meta-analysis, CMAJ, 180, 48, 10.1503/cmaj.080734 Moberley, 2013, Vaccines for preventing pneumococcal infection in adults, Cochrane Database Syst Rev, 1 Jackson, 2003, Effectiveness of pneumococcal polysaccharide vaccine in older adults, N Engl J Med, 348, 1747, 10.1056/NEJMoa022678 Diao, 2016, Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials, Vaccine, 34, 1496, 10.1016/j.vaccine.2016.02.023 Kraicer-Melamed, 2016, The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis, Vaccine, 34, 1540, 10.1016/j.vaccine.2016.02.024 Bonten, 2015, Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults, N Engl J Med, 372, 1114, 10.1056/NEJMoa1408544 Dhoubhadel, 2014, A novel high-throughput method for molecular serotyping and serotype-specific quantification of Streptococcus pneumoniae using a nanofluidic real-time PCR system, J Med Microbiol, 63, 528, 10.1099/jmm.0.071464-0 Naito, 2014, Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the Great East Japan Earthquake, J Infect Chemother, 20, 450, 10.1016/j.jiac.2014.03.004 Chiba, 2014, Changes in capsule and drug resistance of pneumococci after introduction of PCV7, Japan, 2010-2013, Emerg Infect Dis, 20, 1132, 10.3201/eid2007.131485 Orenstein, 2007, Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness, Int J Epidemiol, 36, 623, 10.1093/ije/dym021 De Serres, 2013, The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials, Euro Surveill, 18, 10.2807/1560-7917.ES2013.18.37.20585 Haber, 2015, A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies, Epidemiol Infect, 143, 1417, 10.1017/S0950268814002179 2005, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST Gutierrez Rodriguez, 2014, Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011, Euro Surveill, 19, 20922, 10.2807/1560-7917.ES2014.19.40.20922 Wiemken, 2014, Vaccine, 32, 2198, 10.1016/j.vaccine.2014.02.048 Austrian, 1976, Prevention of pneumococcal pneumonia by vaccination, Trans Assoc Am Physicians, 89, 184 Smit, 1977, Protective efficacy of pneumococcal polysaccharide vaccines, JAMA, 238, 2613, 10.1001/jama.1977.03280250039019 Cook, 2009, Sex differences in injection site reactions with human vaccines, Hum Vaccin, 5, 441, 10.4161/hv.8476 Voysey, 2016, Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells, Vaccine, 34, 1657, 10.1016/j.vaccine.2016.02.036 Klein, 2010, The Xs and Y of immune responses to viral vaccines, Lancet Infect Dis, 10, 338, 10.1016/S1473-3099(10)70049-9 Ort, 1983, Pneumococcal pneumonia in hospitalized patients. Clinical and radiological presentations, JAMA, 249, 214, 10.1001/jama.1983.03330260032027 Maruyama, 2010, Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial, BMJ, 340, c1004, 10.1136/bmj.c1004 Schiffner-Rohe, 2016, Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk—a systematic review and meta-analysis, PLoS One, 11, e0146338, 10.1371/journal.pone.0146338 Clutterbuck, 2012, Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells, J Infect Dis, 205, 1408, 10.1093/infdis/jis212